CH Biotech R&D Co., Ltd.
Taiwan Stock ExchangeTotal Valuation
CH Biotech R&D Co., Ltd. carries a market capitalization of 9.17B, placing it among publicly traded companies globally. Its enterprise value stands at 8.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.17B |
| Enterprise Value | 8.33B |
Share Statistics
CH Biotech R&D Co., Ltd. currently has 102.80M shares outstanding.
| Shares Outstanding | 102.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
CH Biotech R&D Co., Ltd. trades at a trailing price-to-earnings ratio of 22.16. The price-to-sales ratio is 4.79, and the price-to-book ratio stands at 4.86.
| PE Ratio | 22.16 |
| PS Ratio | 4.79 |
| PB Ratio | 4.86 |
| P/TBV Ratio | 3.02 |
| P/FCF Ratio | 16.44 |
| P/OCF Ratio | 24.75 |
Enterprise Valuation
On an enterprise value basis, CH Biotech R&D Co., Ltd. trades at an EV/EBITDA multiple of 15.36 and an EV/FCF ratio of 16.50. The EV/Sales ratio of 4.95 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.36 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.95 |
| EV / EBITDA | 15.36 |
| EV / EBIT | 15.36 |
| EV / FCF | 16.50 |
Financial Position
CH Biotech R&D Co., Ltd. maintains a current ratio of 1.22, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.18, indicating elevated leverage, while an interest coverage ratio of 33.93 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.22 |
| Quick Ratio | 0.70 |
| Debt / Equity | 33.18 |
| Debt / EBITDA | 1.64 |
| Interest Coverage | 33.93 |
Financial Efficiency
CH Biotech R&D Co., Ltd. posts a return on equity of 22.46 and a return on invested capital of 12.55.
| Return on Equity (ROE) | 22.46 |
| Return on Assets (ROA) | 9.77 |
| Return on Invested Capital (ROIC) | 12.55 |
| Return on Capital Employed (ROCE) | 15.48 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.86 |
Taxes
Over the trailing twelve months, CH Biotech R&D Co., Ltd. has paid 77.70M in income taxes, reflecting an effective tax rate of 17.60.
| Income Tax | 77.70M |
| Effective Tax Rate | 17.60 |
Stock Price Statistics
CH Biotech R&D Co., Ltd.'s stock has gained approximately 16.66667% over the past 52 weeks. The 50-day moving average sits at 93.24, while the 200-day moving average is 93.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | 16.66667% |
| 50-Day Moving Average | 93.24 |
| 200-Day Moving Average | 93.38 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CH Biotech R&D Co., Ltd. generated 1.68B in revenue and converted that into 364.31M in net income, yielding earnings per share of 3.54. EBITDA reached 542.33M, while operating income came in at 542.33M.
| Revenue | 1.68B |
| Gross Profit | 1.41B |
| Operating Income | 542.33M |
| Pretax Income | 441.51M |
| Net Income | 364.31M |
| EBITDA | 542.33M |
| EBIT | 542.33M |
| Earnings Per Share (EPS) | 3.54 |
Balance Sheet
CH Biotech R&D Co., Ltd. holds 629.59M in cash and equivalents against 888.66M in total debt, resulting in a net debt position of 101.24M. Total book value stands at 1.66B, with working capital of 198.89M providing operational flexibility.
| Cash & Cash Equivalents | 629.59M |
| Total Debt | 888.66M |
| Net Debt | 101.24M |
| Equity (Book Value) | 1.66B |
| Book Value Per Share | 16.16 |
| Working Capital | 198.89M |
Cash Flow
CH Biotech R&D Co., Ltd. produced 326.23M in operating cash flow over the past twelve months. After subtracting -165.65M in capital expenditures, free cash flow totaled 160.58M - equivalent to 1.56 per share.
| Operating Cash Flow | 326.23M |
| Capital Expenditures | -165.65M |
| Free Cash Flow | 160.58M |
| FCF Per Share | 1.56 |
Margins
CH Biotech R&D Co., Ltd. operates with a gross margin of 83.46, reflecting its pricing power and cost economics. The operating margin of 32.20 and net profit margin of 21.63 provide insight into operational efficiency.
| Gross Margin | 83.46 |
| Operating Margin | 32.20 |
| Pretax Margin | 26.21 |
| Profit Margin | 21.63 |
| EBITDA Margin | 32.20 |
Dividends & Yields
The company's payout ratio of 14.15 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.50 |
| Dividend Yield | N/A |
| Payout Ratio | 14.15 |
| Shareholder Yield | 4.13 |
| FCF Yield | 6.08 |
Scores
CH Biotech R&D Co., Ltd. posts an Altman Z-Score of 5.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.42 |